Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03266640 · ClinicalTrials.gov registry record · Phase 2
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
A Phase 2 study of Cytomegalovirus Infections and Primary Immune Deficiency Disorder, sponsored by New York Medical College.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 9
- Study locations
NCT03266640: Recruiting Phase 2 study of Cytomegalovirus Infections and Primary Immune Deficiency Disorder, sponsored by New York Medical College.
NCT03266640 is a Phase 2 study of Cytomegalovirus Infections and Primary Immune Deficiency Disorder that is actively recruiting participants, run by New York Medical College. The registered enrollment target is 20 participants, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (90% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03266640, a Phase 2 study of Cytomegalovirus Infections and Primary Immune Deficiency Disorder, is actively recruiting participants, sponsored by New York Medical College.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 9
- Study locations
Study Summary
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Primary Outcome
Patients will be monitored for adverse events following the administration of CMV CTLs
Conditions Studied
Interventions
- DRUG viral specific cytotoxic t-lymphocytes
Study Locations (9)
California
- Children's Hospital Los Angeles - Los Angeles
- University of California San Francisco - San Francisco
Indiana
- Indiana University - Indianapolis
Maryland
- Johns Hopkins - Baltimore
Missouri
- Washington University - St Louis
New York
- New York Medical College - Valhalla
Ohio
- Nationwide Children's Hosptial - Columbus
Pennsylvania
- Children's Hospital of Pennsylvania - Philadelphia
Wisconsin
- Medical College of Wisconsin/Children's Hospital of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT03266640 shows while recruiting
NCT03266640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which viral specific cytotoxic t-lymphocytes is the first listed.
NCT03266640 lists 9 locations in 8 states (California, Indiana, Maryland).
Frequently Asked Questions
What is clinical trial NCT03266640 about?
NCT03266640 is a clinical study titled "Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)". CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary...
What is the current status of trial NCT03266640?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-11-01. Estimated completion is 2027-12-31.
What conditions does trial NCT03266640 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections, Primary Immune Deficiency Disorder.
What interventions are being tested in trial NCT03266640?
The interventions under investigation include: viral specific cytotoxic t-lymphocytes (DRUG).
Who is sponsoring clinical trial NCT03266640?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03266640 being conducted?
This trial has 9 study locations across California, Indiana, Maryland, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03266640's enrollment target sits among peer trials
20 22nd of 24 higher than 1 of 24 other Cytomegalovirus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cytomegalovirus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
RECRUITING · Phase 2
-
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
COMPLETED · Phase 2
-
Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)
COMPLETED · Phase 2
-
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
COMPLETED · Phase 2
-
Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors
COMPLETED · Phase 2
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI